vimarsana.com

Page 63 - மருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DRAP s Central Drug Laboratory to Get WHO Accreditation

The Drug Regulatory Authority of Pakistan (DRAP) is upgrading its Central Drugs Laboratory (CDL) which will soon be accreditated by the World Health

Drug regulatory authority of pakistanWorld health organizationCentral drug laboratoryCentral drugs laboratoryDrug regulatory authorityமருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்மைய மருந்து ஆய்வகம்மைய மருந்துகள் ஆய்வகம்மருந்து ஒழுங்குமுறை அதிகாரம்

DRAP s Central Drug Laboratory to get WHO accreditation

DRAP s Central Drug Laboratory to get WHO accreditation
thenews.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thenews.com.pk Daily Mail and Mail on Sunday newspapers.

United statesDrug regulatory authority of pakistanWorld health organizationCentral drugs laboratoryDrug regulatory authorityUnited states pharmacopoeiaFederal inspectorsஒன்றுபட்டது மாநிலங்களில்மருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான்உலகம் ஆரோக்கியம் ஆர்கநைஸேஶந்மைய மருந்துகள் ஆய்வகம்மருந்து ஒழுங்குமுறை அதிகாரம்ஒன்றுபட்டது மாநிலங்களில் மருந்தகம்கூட்டாட்சியின் ஆய்வாளர்கள்

DRAP makes medicine import, export online

DRAP has made an online system for the procedure of import and export of medicines required for personal usage

Drug regulatory authority of pakistanRegulatory authorityமருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான்ஒழுங்குமுறை அதிகாரம்

Drap okays marketing of CanSinoBIO vaccine

Drap okays marketing of CanSinoBIO vaccine Top Story February 18, 2021 ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has granted ‘Emergency Use Approval’ to the CanSinoBIO Recombinant COVID-19 Vaccine Adenovirus Type 5 Vector (the “Ad5-nCoV”) and its marketing through private and public sectors. The approval has been granted following the communication of the results of the interim analysis of the global phase-III clinical trial of Ad5-nCoV to the Health Ministry by the Independent Data Monitoring Committee (IDMC). The “Ad5-nCoV” has successfully met its pre-specified primary safety and efficacy criteria in the interim analysis. There were no vaccine-related serious adverse events (SAEs) and, therefore, CanSinoBIO has been allowed by IDMC to continue to advance the global phase-III clinical trial of the Ad5-nCoV.

Shifa international hospitalCansino biologics incNational institute of healthDrug regulatory authority of pakistanData monitoring committeeAga khan university hospitalHealth ministryWorld health organisationUniversity of health sciencesPharma pvt ltdDrug regulatory authorityEmergency use approvalAdenovirus typeIndependent data monitoring committeeCansino biologicsWorld health

DRAP Approves Chinese Coronavirus Vaccine For Marketing

DRAP Approves Chinese Coronavirus Vaccine For Marketing
propakistani.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from propakistani.pk Daily Mail and Mail on Sunday newspapers.

Drug regulatory authority of pakistanMinistry of healthDrug regulatory authorityமருந்து ஒழுங்குமுறை அதிகாரம் ஆஃப் பாக்கிஸ்தான்அமைச்சகம் ஆஃப் ஆரோக்கியம்மருந்து ஒழுங்குமுறை அதிகாரம்

vimarsana © 2020. All Rights Reserved.